中西医治疗糖尿病肾病的研究进展
Research Progress in the Treatment of Diabetic Nephropathy with Integrated Traditional Chinese and Western Medicine
摘要: 糖尿病肾病(Diabetic Kidney Disease, DKD)是终末期肾病的主要原因之一,是糖尿病最严重且最常见的微血管病变之一。目前,西医对DKD常通过调节血糖、血脂、降压来治疗,一定程度上可控制疾病的进展,但用药存有不良反应和用药局限性。中医药通过整体调节和辨证论治,在改善症状、减少西药不良反应方面显示出独特优势。此综述主要结合中医病因病机、中医治疗方法、西医诊断、流行病学、危险因素、西医治疗方法以及中西医联合治疗展开论述。旨在总结前人经验,阐述DKD的中西医认识及诊疗方法,为临床提供参考。
Abstract: Diabetic Kidney Disease (DKD) is one of the leading causes of End-Stage Renal Disease (ESRD) and ranks among the most severe and prevalent microvascular complications of diabetes mellitus. Currently, Western medicine primarily intervenes in DKD via glycemic control, lipid regulation and antihypertensive therapy, which can slow disease progression to a certain degree. Nevertheless, Western medications are associated with adverse reactions and inherent limitations in clinical application. Traditional Chinese Medicine (TCM) features holistic regulation and treatment based on syndrome differentiation, and presents unique superiorities in relieving clinical symptoms and mitigating adverse reactions of Western drugs. This review mainly elaborates on DKD from the perspectives of TCM etiology and pathogenesis, TCM therapeutic regimens, Western medical diagnosis, epidemiology, risk factors, Western medical interventions, as well as integrated Chinese and Western medicine therapy. It aims to summarize previous research findings, expound the cognition, diagnosis and treatment approaches of DKD in both TCM and Western medicine, and provide references for clinical practice.
文章引用:张一凡, 刘桠. 中西医治疗糖尿病肾病的研究进展[J]. 亚洲急诊医学病例研究, 2026, 14(2): 255-263. https://doi.org/10.12677/acrem.2026.142032

参考文献

[1] Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B.B., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article 109119. [Google Scholar] [CrossRef] [PubMed]
[2] 郑丽, 刘德军, 张卫娜, 等. 1990年至2021年中国与全球糖尿病肾病负担趋势的分析与比较[J]. 中国临床保健杂志, 2025, 28(6): 804-811.
[3] 高亚斌, 郭敬, 苗润培, 等. 王耀献清热消癥法治疗糖尿病肾病经验[J]. 北京中医药, 2020, 39(2): 152-154.
[4] 董超, 王子辰. 基于吕仁和“肾络微型癥瘕”理论治疗糖尿病肾脏病体悟[J]. 中医药临床杂志, 2022, 34(9): 1627-1631.
[5] 张先闻, 陈以平. 陈以平辨治糖尿病肾病经验撷要[J]. 上海中医药杂志, 2008, 42(6): 6-7.
[6] 黄奡, 张颖, 张兰. 张兰教授基于肾玄府理论论治糖尿病肾病[J]. 辽宁中医药大学学报, 2023, 25(7): 122-125.
[7] 周媛媛, 李中南. 李中南治疗糖尿病肾病经验辑要[J]. 陕西中医药大学学报, 2021, 44(4): 57-60.
[8] 冯建春. 糖尿病肾病从风论治的体会[C]//世界中医药学会联合会糖尿病专业委员会. 世界中医药学会联合会糖尿病专业委员会专家文集(第二十辑). 北京: 首都医科大学中医学院, 2023: 40-44.
[9] 南赫, 黄晓强, 王宣权, 等. 糖尿病肾病“肾络伏风”病机学说及“从风论治”治法的探讨[J]. 环球中医药, 2020, 13(4): 620-623.
[10] 高亚斌, 王珍, 聂安政, 等. “以热为本, 以期为纲”论治早期糖尿病肾病[J]. 中华中医药杂志, 2019, 34(11): 5210-5212.
[11] 向长玉. 活血化瘀药治疗糖尿病肾病作用机制的探讨[C]//中华中医药学会. 中华中医药学会糖尿病分会第十九次全国中医药糖尿病大会资料汇编. 开封: 河南省开封市中医院内分泌科; 郑州: 河南省中医糖尿病医院; 郑州: 河南省中西医结合糖尿病诊疗中心, 2018: 104.
[12] 高亚斌, 王耀献, 郭敬, 等. “以热为本, 以期为纲”论治晚期糖尿病肾病[J]. 中华中医药杂志, 2020, 35(2): 714-716.
[13] 张园, 张世超. 针刺联合中药治疗脾肾气虚型糖尿病肾病的临床研究[J]. 上海针灸杂志, 2021, 40(6): 686-691.
[14] 龙世松, 倪云美, 龙冬娣, 等. 中药灌肠配合肾康注射液治疗Ⅳ期糖尿病肾病患者的效果分析[J]. 大医生, 2023, 8(3): 63-65.
[15] 莫鹃萍, 杨宏杰. 中西医结合治疗糖尿病肾病的研究进展[J]. 光明中医, 2023, 38(14): 2833-2836.
[16] Cundy, T., Holden, A. and Stallworthy, E. (2021) Early Worsening of Diabetic Nephropathy in Type 2 Diabetes after Rapid Improvement in Chronic Severe Hyperglycemia. Diabetes Care, 44, e55-e56. [Google Scholar] [CrossRef] [PubMed]
[17] 刘志超, 高晟玮, 王振兴, 等. 中医药治疗糖尿病肾病机理探讨[J]. 西部中医药, 2021, 34(5): 148-151.
[18] 孙菲. 瑞舒伐他汀联合门冬胰岛素治疗糖尿病肾病的价值分析[J]. 中国实用医药, 2022, 17(15): 147-149.
[19] Kitagawa, N., Ushigome, E., Kitagawa, N., Ushigome, H., Yokota, I., Nakanishi, N., et al. (2022) Diabetic Nephropathy Ameliorated in Patients with Normal Home Blood Pressure Compared to Those with Isolated High Home Systolic Blood Pressure: A 5-Year Prospective Cohort Study among Patients with Type 2 Diabetes Mellitus. Diabetes and Vascular Disease Research, 19, 1-9.
[20] Jaimes, E.A., Zhou, M., Siddiqui, M., Rezonzew, G., Tian, R., Seshan, S.V., et al. (2021) Nicotine, Smoking, Podocytes, and Diabetic Nephropathy. American Journal of Physiology-Renal Physiology, 320, F442-F453. [Google Scholar] [CrossRef] [PubMed]
[21] 陈才铭, 张苗苗, 胡利明. 大黄酸对肥胖糖尿病大鼠肾皮质PPARγ和TGF-β1表达的影响[J]. 中药材, 2015, 38(4): 810-812.
[22] 中华医学会糖尿病学分会. 中国糖尿病肾脏病防治指南(2021年版) [J]. 中华糖尿病杂志, 2021, 13(8): 762-784.
[23] Azagew, A.W., Beko, Z.W. and Mekonnen, C.K. (2024) Determinants of Diabetic Nephropathy among Diabetic Patients in Ethiopia: Systematic Review and Meta-Analysis. PLOS ONE, 19, e0297082. [Google Scholar] [CrossRef] [PubMed]
[24] Liao, X., Zhu, Y. and Xue, C. (2022) Diagnostic Value of Serum Cystatin C for Diabetic Nephropathy: A Meta-Analysis. BMC Endocrine Disorders, 22, Article No. 149. [Google Scholar] [CrossRef] [PubMed]
[25] Ni, L., Yuan, C., Chen, G., Zhang, C. and Wu, X. (2020) SGLT2I: Beyond the Glucose-Lowering Effect. Cardiovascular Diabetology, 19, Article No. 98. [Google Scholar] [CrossRef] [PubMed]
[26] Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383, 1436-1446. [Google Scholar] [CrossRef] [PubMed]
[27] Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380, 2295-2306. [Google Scholar] [CrossRef] [PubMed]
[28] Gragnano, F., De Sio, V. and Calabrò, P. (2024) FLOW Trial Stopped Early Due to Evidence of Renal Protection with Semaglutide. European Heart Journal-Cardiovascular Pharmacotherapy, 10, 7-9. [Google Scholar] [CrossRef] [PubMed]
[29] Mann, J.F.E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., et al. (2024) Effects of Semaglutide with and without Concomitant SGLT2 Inhibitor Use in Participants with Type 2 Diabetes and Chronic Kidney Disease in the FLOW Trial. Nature Medicine, 30, 2849-2856. [Google Scholar] [CrossRef] [PubMed]
[30] Tian, S., Zhou, S., Wu, W., Lin, Y., Wang, T., Sun, H., et al. (2025) GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition. Advanced Science, 12, e2409781. [Google Scholar] [CrossRef] [PubMed]
[31] Agarwal, R., Filippatos, G., Pitt, B., Anker, S.D., Rossing, P., Joseph, A., et al. (2022) Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis. European Heart Journal, 43, 474-484. [Google Scholar] [CrossRef] [PubMed]
[32] Luettges, K., Bode, M., Thiele, A., Ritter, D., Klopfleisch, R., Kappert, K., et al. (2021) Finerenone Reduces Renal RoRgt Gd T-Cells and Protects against Cardiorenal Damage. European Heart Journal, 42, ehab724. [Google Scholar] [CrossRef
[33] 苏淑娟, 林任, 白洁. 复方参芪地黄汤联合西医治疗糖尿病肾病的临床效果研究[J]. 实用医院临床杂志, 2022, 19(2): 104-107.
[34] 华烨, 章勇, 胡琼. 加味当归补血汤联合厄贝沙坦治疗糖尿病肾病疗效及对肾功能、血清免疫因子的影响[J]. 四川中医, 2022, 40(12): 94-97.
[35] 李琪, 高圆圆, 王真, 等. 达格列净联合二甲双胍治疗2型糖尿病肾病患者的临床疗效[J]. 临床合理用药杂志, 2022, 15(36): 20-22, 30.
[36] 邢玉凤. 基于AMPK/ACC通路探究通络地龟汤对糖尿病肾脏病脂代谢紊乱的影响[D]: [硕士学位论文]. 郑州: 河南中医药大学, 2022.
[37] 金珉廷. 益气解毒活络法对早期DN大鼠肾组织SREBP影响机制研究[D]: [博士学位论文]. 沈阳: 辽宁中医药大学, 2013.
[38] 薛青. 益肾泄浊方治疗糖尿病肾病气阴两虚、肾络瘀阻证临床研究[J]. 中医学报, 2017, 32(2): 213-217.